Bit.bio

bit.bio is a synthetic biology company based in Cambridge, UK, founded in 2016 as a spinout from the University of Cambridge. The company specializes in reprogramming human induced pluripotent stem cells (iPSCs) into consistent and scalable cell types for research, drug discovery, and cell therapy. Using proprietary technologies like the opti-ox™ platform, bit.bio can generate billions of cells in days, enhancing research efficiency and lowering costs in cell therapy. The company's core offerings include ioCells, which are iPSC-derived human cells designed for research and drug discovery, and a Cell Coding Platform that allows for the precise creation of any human cell type. bit.bio also develops a therapeutics pipeline aimed at next-generation therapies. With a strong focus on ethics and sustainability, the company is committed to advancing its mission while addressing global challenges. It has raised over £124 million in funding and employs a dedicated team to drive innovation in the field.